From the Research
Plasmalogens are not currently recommended as a standard treatment for autism spectrum disorder (ASD). While some preliminary research suggests that individuals with autism may have lower levels of plasmalogens (a type of phospholipid found in cell membranes), there is insufficient clinical evidence to support their use as a therapeutic intervention. No established dosing guidelines or treatment regimens exist for plasmalogen supplementation in autism.
Key Considerations
- The most recent and highest quality study on autism treatment is the 2019 study on Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial 1, which found that risperidone and aripiprazole are effective in reducing irritability and problem behaviors in autism.
- Applied Behavior Analysis (ABA) is a well-established treatment for autism, with strong evidence of effectiveness in helping people with autism achieve goals 2, 3.
- Any exploration of plasmalogens should be part of a comprehensive treatment plan that includes evidence-based behavioral and educational interventions, which remain the foundation of autism management.
Treatment Approach
- If you're interested in exploring plasmalogen supplementation, it's essential to consult with a healthcare provider who specializes in autism treatment before starting any supplement.
- A comprehensive treatment plan should include evidence-based behavioral and educational interventions, such as ABA, which have been shown to be effective in improving outcomes for individuals with autism.
- Pharmacologic treatments, such as risperidone and aripiprazole, may also be considered for reducing irritability and problem behaviors in autism, under the guidance of a healthcare provider.